Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS.
The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 372 |
| CEO | Christopher Peetz |
Contact Details
Address: 989 East Hillsdale Boulevard, Suite 300 Foster City, California 94404 United States | |
| Phone | 650 667 4085 |
| Website | mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| Employer ID | 83-1281555 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer and Director |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer and President |
| Eric H. Bjerkholt M.B.A., M.S. | Chief Financial Officer |
| Dr. Joanne M. J. Quan M.D. | Chief Medical Officer |
| Dr. Jean-Luc Girardet Ph.D. | Chief Technical Officer |
| Andrew McKibben | Senior Vice President, Strategic Finance and Investor Relations |
| Douglas T. Sheehy J.D. | Chief Legal Officer and Secretary |
| Meredith Kiernan | Senior Director of Global Corporate Communications |
| Erin Campany | Chief People Officer |
| Lara Longpre MBA, MSC | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| May 4, 2026 | 8-K | Current Report |
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2026 | 144 | Filing |
| Apr 8, 2026 | 8-K/A | [Amend] Current report |